Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts).

Lung Cancer - Non-Small Cell Metastatic
Session Type and Session Title: 
Oral Abstract Session, Lung Cancer - Non-small Cell Metastatic
Abstract Number: 
J Clin Oncol 31, 2013 (suppl; abstr 8000)
Fabrice Barlesi, Helene Blons, Michele Beau-Faller, Isabelle Rouquette, L'houcine Ouafik, Jean Mosser, Jean-Philippe Merlio, Pierre Paul Bringuier, Philippe Jonveaux, Cedric Le Marechal, Marc G. Denis, Frederique Madeleine Penault-Llorca, Didier Debieuvre, Jean-Charles Soria, Jacques Cadranel, Julien Mazieres, Pascale Missy, Franck Morin, Frederique Nowak, Gerard Zalcman, Intergroupe Francophone de Cancérologie Thoracique (IFCT); Aix Marseille University, Assistance Publique Hôpitaux de Marseille, Hôpital Nord, Marseille, France; Hôpital Européen Georges Pompidou (HEGP), Assistance Publique Hôpitaux de Paris (APHP), Paris, France; Centre Hospitalier Universitaire Strasbourg, Strasbourg, France; Centre Hospitalier Universitaire Toulouse, Toulouse, France; Laboratoire de Transfert, CHU Nord, Marseille, France; Centre Hospitalier Universitaire, Rennes, France; Service de Biologie des Tumeurs - CHU, Bordeaux, France; Hopital Edouard Herriot, Lyon, France; Centre Hospitalier Universitaire, Nancy, France; Laboratoire de Génétique Moléculaire - CHU Morvan, Brest, France; Nantes University Hospital, Nantes, France; Centre Jean Perrin, Clermont-Ferrand, France; Emile Muller Hospital, Mulhouse, France; Institut Gustave Roussy, Villejuif, France; Service de Pneumologie and GRC-04 Theranoscan, Pierre et Marie Curie Université, Hôpital Tenon, Paris, France; Hôpital Larrey CHU Toulouse, Toulouse, France; Intergroupe Francophone de Cancérologie Thoracique, Paris, France; French National Cancer Institute, Boulogne, France; Caen University Hospital, Caen, France

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^).

Abstract Disclosures


Background: Personalized medicine is now a reality for advanced NSCLC pts on the basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French NCI (INCa) also decided to additionally fund the routine assessment of 4 additional BM (HER2, KRAS, BRAF, PI3KCA). Methods: Starting on April 2012, these BM analyses were prospectively collected into a database head by the IFCT (www.ifct.fr) with 15-20,000 analyses awaited after one year. The physicians prescribing each of these BM analyses were then connected to this database and were asked to regularly complete epidemiological, clinical and therapeutic data for each corresponding patient. Results: 10,000 BM analyses were collected and entered into the BM France database at the time of this first analysis (January 2013). On the basis of available data, the patients were mainly male (63.8%), (ex)smokers (83.3%) and stage IV pts (64%). The tumors were mainly adenocarcinomas (76.1%). The samples for BM analysis were collected under bronchoscopy, surgery or transthoracic biopsy in 27.4, 28.1 and 24.2%, respectively. The 10,000 molecular profiles were characterized by 9.4% EGFR (including 0.8% EGFR resistant), 0.9% HER2, 26.9% KRAS, 1.6% BRAF, and 2.6% PI3KCA mutated and 4.0% EML4-ALK fusion genes. Double mutations were seen in 0.9% of the tumors. On January 2013, data on treatment were available for 18.6% of patients among whom 56.9% of patients received a treatment according to their molecular profile (labeled drugs or bio-guided trials). Updated data will be presented during the meeting. Conclusions: Biomarkers France is the largest ever conducted biomolecular study on advanced NSCLC patients and provides solid data on the value of a nationwide BM screening policy for NSCLC patients.